<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332653</url>
  </required_header>
  <id_info>
    <org_study_id>NIT-110 (KEYNOTE A60)</org_study_id>
    <nct_id>NCT04332653</nct_id>
  </id_info>
  <brief_title>NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors</brief_title>
  <acronym>KEYNOTE A60</acronym>
  <official_title>An Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeoImmuneTech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeoImmuneTech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purposes of Phase 1b of this study are to determine the following in participants&#xD;
      with advanced solid tumors:&#xD;
&#xD;
        -  Safety and tolerability of NT-I7 in combination with pembrolizumab&#xD;
&#xD;
        -  Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D)&#xD;
&#xD;
      The main purpose of Phase 2a of this study is to assess the preliminary anti-tumor activity&#xD;
      of NT-I7 in combination with pembrolizumab in participants with checkpoint inhibitor (CPI)&#xD;
      treated and naïve relapsed and refractory (R/R) tumors.&#xD;
&#xD;
      The main purpose of the Biomarker Cohort is to assess a potential correlation between tumor&#xD;
      infiltrating lymphocytes (TILs) and clinical benefits in participants with CPI-naïve R/R&#xD;
      ovarian cancer (OC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label Phase 1b/2a study of NT-I7 in combination with&#xD;
      pembrolizumab. The study consists of a dose escalation phase (Phase 1b) followed by a dose&#xD;
      expansion phase (Phase 2a) and a Biomarker Cohort.&#xD;
&#xD;
      The Phase 1b is designed to assess the safety and tolerability, including determination of&#xD;
      the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of NT-I7.&#xD;
&#xD;
      The main purpose of Phase 2a of this study is to assess the preliminary antitumor activity of&#xD;
      NT-I7 in combination with pembrolizumab in participants with relapsed/refractory&#xD;
&#xD;
        -  checkpoint inhibitor (CPI)-treated Triple Negative Breast Cancer (TNBC), Non-small Cell&#xD;
           Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC)&#xD;
&#xD;
        -  checkpoint inhibitor (CPI)-naïve Microsatellite Stable Colorectal Cancer (MSS-CRC), and&#xD;
           Pancreatic Cancer (PC) The Biomarker Cohort is designed to assess the correlation&#xD;
           between tumor infiltrating lymphocytes (TILs) and clinical benefits of NT-I7 in&#xD;
           combination with pembrolizumab in participants with CPI naïve R/R Ovarian Cancer (OC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Safety and Tolerability of NT-I7 in Combination With Pembrolizumab to Determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of NT-I7</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Incidence, nature and severity of Adverse Events (AEs) graded according to NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0&#xD;
Incidence and nature of Dose-Limiting Toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Safety and Tolerability of NT-I7 in Combination With Pembrolizumab to Determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of NT-I7</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Statistical correlation of dose levels with safety and efficacy parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a: Preliminary Assessment of the Objective Response Rate (ORR) of NT-I7 in Combination with Pembrolizumab</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarker Cohort: Number of Tumor-Infiltrating Lymphocytes (TILs)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarker Cohort: Distribution of Tumor-Infiltrating Lymphocytes (TILs)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>TILs in tumor biopsy samples will be identified using a multi-spectral Immunofluorescence (IF) assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarker Cohort: Phenotype of Tumor-Infiltrating Lymphocytes (TILs)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>TILs in tumor biopsy samples will be identified using a multi-spectral Immunofluorescence (IF) assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (DOR)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience an Increase in Anti-Drug Antibodies (ADAs) to NT-I7</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Cohort: Objective Response Rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, Nature, and Severity of Adverse Events (AEs) graded according to National Cancer Institute Common Terminologies Criteria for Adverse Events (NCI CTCAE) v5.0</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Any Advanced Solid Tumors</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Microsatellite Stable Colorectal Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1b: NT-I7 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NT-I7 will be administered on Day 1 of alternate 21 day cycles (Cycle 1, 3, 5 etc.). Dosage will increase until the maximum tolerated dose (MTD) and/or the recommended phase 2 (RP2D) dose is reached.&#xD;
Pembrolizumab will be administered on Day 1 of every 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a: CPI Treated Triple Negative Breast Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with checkpoint inhibitor (CPI) treated relapsed or refractory triple negative breast cancer (TNBC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.&#xD;
Pembrolizumab will be administered on Day 1 of every 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a: CPI Treated Non-small Cell Lung Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with checkpoint inhibitor (CPI) treated relapsed or refractory non-small cell lung cancer (NSCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.&#xD;
Pembrolizumab will be administered on Day 1 of every 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a: CPI Treated Small Cell Lung Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with checkpoint inhibitor (CPI) treated relapsed or refractory small cell lung cancer (SCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.&#xD;
Pembrolizumab will be administered on Day 1 of every 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a: CPI Naïve Microsatellite Stable Colorectal Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory microsatellite stable colorectal cancer (MSS-CRC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.&#xD;
Pembrolizumab will be administered on Day 1 of every 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a: CPI Naïve Pancreatic Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory pancreatic cancer (PC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.&#xD;
Pembrolizumab will be administered on Day 1 of every 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker Cohort: CPI Naïve Ovarian Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory ovarian cancer (OC). Participants will receive a starting dose of 960 µg/kg of NT-I7 and a fixed dose of 200 mg of pemprolizumab.&#xD;
Pembrolizumab will be administered on Day 1 of every 21 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NT-I7</intervention_name>
    <description>Administered by intramuscular (IM) injection</description>
    <arm_group_label>Biomarker Cohort: CPI Naïve Ovarian Cancer</arm_group_label>
    <arm_group_label>Phase 1b: NT-I7 Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2a: CPI Naïve Microsatellite Stable Colorectal Cancer</arm_group_label>
    <arm_group_label>Phase 2a: CPI Naïve Pancreatic Cancer</arm_group_label>
    <arm_group_label>Phase 2a: CPI Treated Non-small Cell Lung Cancer</arm_group_label>
    <arm_group_label>Phase 2a: CPI Treated Small Cell Lung Cancer</arm_group_label>
    <arm_group_label>Phase 2a: CPI Treated Triple Negative Breast Cancer</arm_group_label>
    <other_name>Efineptakin alfa</other_name>
    <other_name>rhIL-7-hyFc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered by intravenous (IV) injection</description>
    <arm_group_label>Biomarker Cohort: CPI Naïve Ovarian Cancer</arm_group_label>
    <arm_group_label>Phase 1b: NT-I7 Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2a: CPI Naïve Microsatellite Stable Colorectal Cancer</arm_group_label>
    <arm_group_label>Phase 2a: CPI Naïve Pancreatic Cancer</arm_group_label>
    <arm_group_label>Phase 2a: CPI Treated Non-small Cell Lung Cancer</arm_group_label>
    <arm_group_label>Phase 2a: CPI Treated Small Cell Lung Cancer</arm_group_label>
    <arm_group_label>Phase 2a: CPI Treated Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (Participants must meet all the following to be eligible)&#xD;
&#xD;
          -  Participants with histologically or cytologically confirmed advanced or metastatic&#xD;
             solid tumors.&#xD;
&#xD;
          -  Have measurable disease per RECIST v1.1.&#xD;
&#xD;
          -  Participants enrolling in the Phase 1b, Arms I, IV, and V of the Phase 2a, and the&#xD;
             Biomarker Cohort must have biopsiable disease.&#xD;
&#xD;
          -  Female participants who are either postmenopausal for at least 1 year, are surgically&#xD;
             sterile for at least 6 weeks; female participants of childbearing potential must agree&#xD;
             to remain abstinent (refrain from heterosexual intercourse) or to use dual methods of&#xD;
             contraception for the duration of study treatment and for 120 days after the last dose&#xD;
             of study treatment (pembrolizumab and/or NT-I7).&#xD;
&#xD;
          -  Non-sterile male participants who are sexually active with female partners of&#xD;
             childbearing potential must agree to remain abstinent (refrain from heterosexual&#xD;
             intercourse) or to use highly effective method(s) of contraception for the duration of&#xD;
             study treatment and for 120 days after the last dose of study treatment (pembrolizumab&#xD;
             and/or NT-I7).&#xD;
&#xD;
          -  Meet the requirements for the intended stages and arms (disease specific inclusion&#xD;
             criteria), as follows:&#xD;
&#xD;
        Applicable to the Dose escalation phase (Phase 1b) only: (Biopsy Arm)&#xD;
&#xD;
          -  Relapsed/refractory advanced solid tumors.&#xD;
&#xD;
        Applicable to the Dose expansion phase (Phase 2a) only:&#xD;
&#xD;
        Anti-PD-1/anti-PD-L1 refractory criteria for CPI-treated TNBC, NSCLC, and SCLC&#xD;
&#xD;
          -  Has received at least 2 doses of an approved anti-PD-1/anti-PD-L1 monoclonal antibody&#xD;
             (mAb).&#xD;
&#xD;
          -  Has demonstrated disease progression after anti-PD-1/anti-PD-L1.&#xD;
&#xD;
        Specific to Arm I: CPI-treated R/R TNBC (Biopsy Arm)&#xD;
&#xD;
          -  Histopathologic or cytologic documented TNBC.&#xD;
&#xD;
          -  Received one or more prior therapies for TNBC in the advanced or metastatic setting,&#xD;
             and prior treatment (for advanced, metastatic or (neo) adjuvant).&#xD;
&#xD;
        Specific to Arm II: CPI-treated R/R NSCLC&#xD;
&#xD;
          -  Had prior treatment with CPI. Participants with estimated glomerular filtration rate&#xD;
             (EGFR), BRAF, or c-ros oncogene 1(ROS1) mutations or anaplastic lymphoma kinase (ALK)&#xD;
             translocations are required to have received prior therapy with the appropriate&#xD;
             tyrosine kinase inhibitor (TKI).&#xD;
&#xD;
        Specific to Arm III: CPI-treated R/R SCLC&#xD;
&#xD;
          -  Recurrent extensive-stage SCLC; Received prior CPI therapy.&#xD;
&#xD;
        Specific to Arm IV: CPI-naïve R/R MSS-CRC (Biopsy Arm)&#xD;
&#xD;
          -  MSS-CRC (categorized as MSS by immunohistochemistry(IHC) or polymerase chain reaction&#xD;
             (PCR).&#xD;
&#xD;
          -  Previously treated with standard therapies, which must include fluoropyrimidine,&#xD;
             oxaliplatin, and irinotecan; participants treated with CPI are not eligible.&#xD;
&#xD;
        Specific to Arm V: CPI-naïve R/R Pancreatic Cancer (Biopsy Arm)&#xD;
&#xD;
          -  Have documented radiographic progression to or documented in tolerance of first line&#xD;
             systemic chemotherapy which included either gemcitabine or Fluorouracil (5-FU)-based&#xD;
             regimen (including capecitabine); participants treated previously with CPI are not&#xD;
             eligible.&#xD;
&#xD;
        Specific to Arm VI Biomarker Cohort: CPI-naïve R/R Ovarian Cancer&#xD;
&#xD;
          -  Up to 5 prior lines of treatment, including platinum-based treatment(s); participants&#xD;
             treated previously with CPIs are not eligible.&#xD;
&#xD;
          -  Willing to provide pre- and on-treatment tumor biopsies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, lactating or breastfeeding.&#xD;
&#xD;
          -  Receiving chemotherapy or any anti-cancer therapy (approved or investigational) with&#xD;
             half-life &lt;1 week within 30 days or 5 half-lives.&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Participants with previously treated brain metastases may participate if&#xD;
             stable.&#xD;
&#xD;
          -  Participants who have received treatment with systemic immunosuppressive medications.&#xD;
&#xD;
          -  Has a history of non-infectious pneumonitis that required steroids or current&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant or bone marrow transplant.&#xD;
&#xD;
          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with&#xD;
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,&#xD;
             CTLA-4, OX-40, CD137) and was discontinued from that treatment due to a Grade 3 or&#xD;
             higher Immune related adverse event (irAE).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>NIT Medical Director</last_name>
    <phone>301-250-4926</phone>
    <email>NIT110@neoimmunetech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffit Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Kim Richard</last_name>
      <phone>813-745-1432</phone>
      <email>richard.kim@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Hirva Mamdani</last_name>
      <phone>313-576-8711</phone>
      <email>mamdanih@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Daniel Morgensztern</last_name>
      <phone>314-362-5817</phone>
      <email>danielmorgensztern@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Tian Zhang</last_name>
      <phone>919-668-4667</phone>
      <email>tian.zhang2@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Anthony Olszanskiy</last_name>
      <phone>215-214-1676</phone>
      <email>anthony.olszanski@fccc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Johanna Bendell</last_name>
      <phone>615-329-6834</phone>
      <email>jbendell@tnonc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Naing</last_name>
      <phone>713-563-1930</phone>
      <email>anaing@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NT-I7 (Efineptakin alfa)</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Lung</keyword>
  <keyword>Breast</keyword>
  <keyword>Pancreas</keyword>
  <keyword>Colorectal</keyword>
  <keyword>Non-small Cell Lung</keyword>
  <keyword>Small Cell Lung</keyword>
  <keyword>Thoracic Neoplasms</keyword>
  <keyword>Interleukin 7</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Cancer</keyword>
  <keyword>Programmed cell death protein (PD-1)</keyword>
  <keyword>Ovarian</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

